<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22388" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gram-Positive Bacteria</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sizar</surname>
            <given-names>Omeed</given-names>
          </name>
          <aff>St. Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Unakal</surname>
            <given-names>Chandrashekhar G.</given-names>
          </name>
          <aff>The University of the West Indies</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omeed Sizar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chandrashekhar Unakal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22388.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Gram-positive organisms have highly variable growth and resistance patterns. The SCOPE project (Surveillance and Control of Pathogens of Epidemiologic Importance) found that in those with an underlying malignancy, gram-positive organisms accounted for 62 percent of all bloodstream infections in 1995 and 76 percent in 2000 while gram-negative organisms accounted for 22 percent in 1995 and 14 percent in 2000. This activity reviews the evaluation and management of gram-positive bacterial infections and explains the role of the interprofessional team in improving care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain how to evaluate for a gram-positive bacterial infection.</p></list-item><list-item><p>Identify common infections caused by gram-positive bacteria.</p></list-item><list-item><p>Describe treatment strategies for gram-positive bacterial infections.</p></list-item><list-item><p>Outline interprofessional team strategies to improve care coordination and communication to provide quality care to patients with gram-positive bacterial infections.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22388&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22388">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22388.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Health professionals need to understand the important difference between gram-positive and gram-negative bacteria. Gram-positive bacteria are bacteria classified by the color they turn&#x000a0;in the staining method. Hans Christian Gram developed the staining method in 1884. The staining method&#x000a0;uses crystal violet dye, which is retained by the thick peptidoglycan cell wall found in gram-positive organisms.&#x000a0;This reaction gives gram-positive organisms a blue color when viewed under a microscope. Although gram-negative organisms classically have an outer membrane, they have a thinner peptidoglycan layer, which does not hold the blue dye used in the initial dying process.&#x000a0;Other information used to differentiate bacteria is the shape. Gram-positive&#x000a0;bacteria comprise cocci, bacilli, or branching filaments.</p>
      </sec>
      <sec id="article-22388.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Gram-positive cocci include&#x000a0;<italic toggle="yes">Staphylococcus</italic> (catalase-positive), which grows clusters, and <italic toggle="yes">Streptococcus </italic>(catalase-negative), which grows in chains.&#x000a0;The&#x000a0;staphylococci further subdivide into coagulase-positive (<italic toggle="yes">S. aureus</italic>) and coagulase-negative (<italic toggle="yes">S. epidermidis</italic> and <italic toggle="yes">S. saprophyticus</italic>) species. Streptococcus bacteria&#x000a0;subdivide into <italic toggle="yes">Strep. pyogenes</italic>&#x000a0;(Group A), <italic toggle="yes">Strep. agalactiae</italic>&#x000a0;(Group B), enterococci&#x000a0;(Group&#x000a0;D), <italic toggle="yes">Strep viridans</italic>, and <italic toggle="yes">Strep pneumonia</italic>.</p>
        <p>Gram-positive bacilli (rods)&#x000a0;subdivide according to their ability to produce spores. <italic toggle="yes">Bacillus</italic> and <italic toggle="yes">Clostridia</italic> are spore-forming&#x000a0;rods while <italic toggle="yes">Listeria</italic> and <italic toggle="yes">Corynebacterium</italic> are not. Spore-forming rods that produce spores can survive in environments for many years. Also, the branching filament rods&#x000a0;encompass Nocardia&#x000a0;and actinomyces.&#x000a0;</p>
        <p>Gram-positive organisms have a thicker peptidoglycan cell wall compared with gram-negative bacteria. It is a 20&#x000a0;to 80 nm thick polymer while the peptidoglycan layer of the gram-negative cell wall is 2 to 3 nm thick and covered with an outer&#x000a0;lipid bilayer membrane.</p>
      </sec>
      <sec id="article-22388.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Bloodstream infection mortality rates have increased by 78% in just two decades<xref ref-type="bibr" rid="article-22388.r1">[1]</xref>.&#x000a0;Gram-positive organisms&#x000a0;have highly variable growth and resistance patterns. The SCOPE project (Surveillance and Control of Pathogens of Epidemiologic Importance) found that gram-positive&#x000a0;organisms in those with an underlying malignancy accounted for 62% of all bloodstream infections in 1995 and 76% in 2000 while gram-negative organisms accounted for 22% and 14% of infections for these years.<xref ref-type="bibr" rid="article-22388.r2">[2]</xref></p>
      </sec>
      <sec id="article-22388.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Gram-positive&#x000a0;cocci:</p>
        <p><italic toggle="yes">Staphylococcus aureus</italic> is a gram-positive, catalase-positive, coagulase-positive cocci in clusters. <italic toggle="yes">S. aureus</italic> can&#x000a0;cause inflammatory diseases, including skin infections, pneumonia, endocarditis, septic arthritis, osteomyelitis, and abscesses. <italic toggle="yes">S. aureus</italic> can also cause toxic shock syndrome (TSST-1), scalded skin syndrome (exfoliative toxin, and food poisoning (enterotoxin).&#x000a0;</p>
        <p><italic toggle="yes">Staphylococcus epidermidis</italic>&#x000a0;is a gram-positive, catalase-positive, coagulase-negative cocci in clusters and is novobiocin sensitive. <italic toggle="yes">S. epidermidis</italic> commonly infects prosthetic devices and IV catheters producing biofilms. <italic toggle="yes">Staphylococcus saprophyticus</italic>&#x000a0;is novobiocin resistant and is a normal flora of the genital tract and perineum. <italic toggle="yes">S. saprophyticus</italic>&#x000a0;accounts for the second most common cause of uncomplicated urinary tract infection (UTI).&#x000a0;</p>
        <p><italic toggle="yes">Streptococcus pneumoniae</italic>&#x000a0;is a gram-positive, encapsulated, lancet-shaped diplococci, most commonly causing otitis media, pneumonia, sinusitis, and meningitis. <italic toggle="yes">Streptococcus viridans</italic>&#x000a0;consist of Strep<italic toggle="yes">. mutans</italic>&#x000a0;and <italic toggle="yes">Strep mitis</italic> found in the normal flora of the oropharynx commonly cause dental carries and subacute bacterial endocarditis (Strep. sanguinis).</p>
        <p><italic toggle="yes">Streptococcus pyogenes</italic>&#x000a0;is a gram-positive group A cocci that can cause pyogenic infections&#x000a0;(pharyngitis, cellulitis, impetigo, erysipelas), toxigenic infections (scarlet fever, necrotizing fasciitis), and immunologic infections (glomerulonephritis and rheumatic fever). ASO titer detects <italic toggle="yes">S. pyogenes</italic> infections.</p>
        <p><italic toggle="yes">Streptococcus agalactiae</italic> is a gram-positive group B cocci that colonize the vagina and is found mainly in babies. Pregnant women need screening&#x000a0;for Group-B Strep&#x000a0;(GBS) at 35&#x000a0;to 37 weeks of gestation.&#x000a0;</p>
        <p>Enterococci is a gram-positive&#x000a0;group D cocci found mainly in the colonic flora and can cause biliary tract infections and UTIs. Vancomycin-resistant&#x000a0;enterococci (VRE) are an important cause of nosocomial infections.&#x000a0;</p>
        <p>Gram-positive rods:</p>
        <p>Clostridia is a gram-positive spore-forming&#x000a0;rod consisting of <italic toggle="yes">C. tetani</italic>, <italic toggle="yes">C. botulinum</italic>, <italic toggle="yes">C. perfringens</italic>, and <italic toggle="yes">C. difficile</italic>. <italic toggle="yes">C. difficile</italic> is often secondary to antibiotic use (clindamycin/ampicillin), PPI use, and recent hospitalization. Treatment involves primarily with oral vancomycin.</p>
        <p><italic toggle="yes">Bacillus anthracis</italic> is a gram-positive spore-forming rod that produces anthrax toxin resulting in an ulcer with a black eschar. <italic toggle="yes">Bacillus cereus</italic> is a gram-positive&#x000a0;rod that can be acquired from spores surviving under-cooked&#x000a0;or reheated rice. Symptoms include nausea, vomiting, and watery non-bloody diarrhea.&#x000a0;</p>
        <p><italic toggle="yes">Corynebacterium diphtheria</italic> is a gram-positive&#x000a0;club-shaped rod that can cause pseudomembranous pharyngitis, myocarditis, and arrhythmias. Toxoid vaccines prevent diphtheria.</p>
        <p><italic toggle="yes">Listeria monocytogenes</italic> is a gram-positive rod acquired by the ingestion of cold deli meats and unpasteurized dairy products or by vaginal transmission during birth. <italic toggle="yes">Listeria</italic> can cause neonatal meningitis, meningitis in immunocompromised patients, gastroenteritis, and septicemia. Treatment includes ampicillin.&#x000a0;</p>
      </sec>
      <sec id="article-22388.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>It is important to identify patients with sepsis and order&#x000a0;necessary blood cultures and labs.&#x000a0;</p>
        <p>
<bold>Physical</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bullous impetigo</p>
          </list-item>
          <list-item>
            <p>Draining sinus tracts</p>
          </list-item>
          <list-item>
            <p>Erythema</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Murmur if endocarditis is present</p>
          </list-item>
          <list-item>
            <p>Petechiae if toxic shock syndrome is present</p>
          </list-item>
          <list-item>
            <p>Superficial abscesses</p>
          </list-item>
          <list-item>
            <p>Warmth</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22388.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Once a gram-positive organism infection is suspected, these laboratory studies are useful:</p>
        <list list-type="bullet">
          <list-item>
            <p>CBC</p>
          </list-item>
          <list-item>
            <p>Electrolytes</p>
          </list-item>
          <list-item>
            <p>Blood cultures</p>
          </list-item>
          <list-item>
            <p>Pro-calcitonin level</p>
          </list-item>
          <list-item>
            <p>Echocardiogram&#x000a0;if endocarditis is suspected</p>
          </list-item>
          <list-item>
            <p>Joint aspiration if a septic joint is suspected</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22388.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Penicillin was the first antibiotic ever introduced during World War II by Alexander Fleming in 1928. Penicillin does not cover Staph or Enterococcus but used mainly streptococcal infections. The penicillinase-resistant organisms (nafcillin, oxacillin, cloxacillin, dicloxacillin) cover Staph (MSSA) and Strep. Anti-pseudomonal penicillins&#x000a0;include piperacillin and ticarcillin effective against gram-positive, gram-negative, pseudomonas, and anaerobes. Carbapenems cover gram-positives, gram negatives, and anaerobes.<xref ref-type="bibr" rid="article-22388.r3">[3]</xref><xref ref-type="bibr" rid="article-22388.r4">[4]</xref><xref ref-type="bibr" rid="article-22388.r5">[5]</xref></p>
        <p>Trimethoprim/sulfamethoxazole, clindamycin, and doxycycline are oral antibiotics used for mild to moderate&#x000a0;MRSA infections.&#x000a0;It is important to note that trimethoprim/sulfamethoxazole increases warfarin levels leading to increased INR. Vancomycin, linezolid, daptomycin, and tigecycline cover moderate to&#x000a0;severe community and hospital-acquired MRSA. Vancomycin requires renal dosing with trough levels between 15&#x000a0;to 20. Linezolid is an option if a patient is allergic to vancomycin. CBC needs to be checked weekly to avoid bone marrow suppression, neutropenia, thrombocytopenia, and anemia. Linezolid, daptomycin, and tigecycline&#x000a0;are options to treat vancomycin-resistant enterococci.<xref ref-type="bibr" rid="article-22388.r6">[6]</xref><xref ref-type="bibr" rid="article-22388.r7">[7]</xref><xref ref-type="bibr" rid="article-22388.r8">[8]</xref></p>
      </sec>
      <sec id="article-22388.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Bacteremia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bronchiectasis imaging</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chemical burns</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Electrical injuries in emergency Medicine</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Emergent management of acute otitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Emergent management of thermal burns</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Empyema imaging</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fever in the infant and toddler</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fever without a focus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Henoch-schonlein purpura</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hospital-acquired infections</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ingrown nails</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Necrotizing enterocolitis &#x000a0;imaging</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22388.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis following infection with gram-positive organisms is variable. The highest mortality rates are in elderly persons who tend to&#x000a0;have suppressed immune systems and less physiologic reserve.</p>
      </sec>
      <sec id="article-22388.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Health professionals, including doctors, nurses, and pharmacists, need to be aware of risk factors to treat patients with selected antibiotics properly. Pharmacists need to accurately monitor vancomycin trough levels to avoid mortality in patients with Staph aureus. They also need to review medication for dose and interactions and counsel patients about finishing all prescribed antibiotics. Infection control nurses evaluate nosocomial infections and implement appropriate policies. An interprofessional approach will produce the best outcomes. [Level 5]</p>
        <p>Outcomes: Screening for methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) risk factors enhance infection control. MRSA risk factors include patients who&#x000a0;are above age 65, urinary catheter, previous antibiotic treatment past three months, trauma, and those admitted from a long-term facility.<xref ref-type="bibr" rid="article-22388.r9">[9]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-22388.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22388&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22388">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/gram-positive-bacteria/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22388">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22388/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22388">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22388.s13">
        <fig id="article-22388.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Gram Stain of <italic toggle="yes">Staphylococcus aureus</italic> Contributed by Scott Jones, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="S.aureus" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22388.s14">
        <title>References</title>
        <ref id="article-22388.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <article-title>National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000.</article-title>
            <source>Am J Infect Control</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>429</fpage>
            <page-range>429-48</page-range>
            <pub-id pub-id-type="pmid">11114613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22388.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wisplinghoff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seifert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Edmond</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States.</article-title>
            <source>Clin Infect Dis</source>
            <year>2003</year>
            <month>May</month>
            <day>01</day>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>1103</fpage>
            <page-range>1103-10</page-range>
            <pub-id pub-id-type="pmid">12715303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22388.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Righi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carnelutti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bassetti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Current role of oxazolidinones and lipoglycopeptides in skin and soft tissue infections.</article-title>
            <source>Curr Opin Infect Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-129</page-range>
            <pub-id pub-id-type="pmid">30664028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22388.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zamoner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Prado</surname>
                <given-names>IRS</given-names>
              </name>
              <name>
                <surname>Balbi</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ponce</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice.</article-title>
            <source>Clin Exp Pharmacol Physiol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>292</fpage>
            <page-range>292-301</page-range>
            <pub-id pub-id-type="pmid">30623980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22388.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rogalla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bomar</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <chapter-title>Listeria Monocytogenes</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30521259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22388.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rostkowska</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Szymanek-Pasternak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous bacterial peritonitis - therapeutic challenges in the era of increasing drug resistance of bacteria.</article-title>
            <source>Clin Exp Hepatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>224</fpage>
            <page-range>224-231</page-range>
            <pub-id pub-id-type="pmid">30603669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22388.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gashaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berhane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bekele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kibru</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Teshager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yilma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fentahun</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Assefa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wieser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gudina</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study.</article-title>
            <source>Antimicrob Resist Infect Control</source>
            <year>2018</year>
            <volume>7</volume>
            <fpage>138</fpage>
            <pub-id pub-id-type="pmid">30479751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22388.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolia</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Tsiodras</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chloros</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Kaspiris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarlikiotis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Savvidou</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Papagelopoulos</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>A Review of Novel Antibiotic Regimens for the Treatment of Orthopedic Infections.</article-title>
            <source>Orthopedics</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>323</fpage>
            <page-range>323-328</page-range>
            <pub-id pub-id-type="pmid">30452066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22388.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Callejo-Torre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eiros Bouza</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Olaechea Astigarraga</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coma Del Corral</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Palomar Mart&#x000ed;nez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alvarez-Lerma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Pueyo</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for methicillin-resistant Staphylococcus aureus colonisation or infection in intensive care units and their reliability for predicting MRSA on ICU admission.</article-title>
            <source>Infez Med</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>201</fpage>
            <page-range>201-9</page-range>
            <pub-id pub-id-type="pmid">27668900</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
